Karyopharm sees FY25 revenue $140M-$155M, consensus $165.5M
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Feb 19 2025
0mins
Revenue Forecast: Total revenue is projected to be between $140 million and $155 million.
Revenue Composition: This total includes U.S. XPOVIO net product revenue as well as license, royalty, and milestone revenue from partners.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy KPTI?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on KPTI
Wall Street analysts forecast KPTI stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for KPTI is 13.83 USD with a low forecast of 6.00 USD and a high forecast of 21.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
6 Analyst Rating
5 Buy
1 Hold
0 Sell
Strong Buy
Current: 6.630
Low
6.00
Averages
13.83
High
21.00
Current: 6.630
Low
6.00
Averages
13.83
High
21.00
About KPTI
Karyopharm Therapeutics Inc. is a commercial-stage pharmaceutical company. The Company is engaged in the discovery, development and commercialization of drugs directed against nuclear export for the treatment of cancer and other diseases. It is developing and commercializing small molecule Selective Inhibitor of Nuclear Export (SINE) compounds that inhibit the nuclear export protein exportin 1 (XPO1). Its lead asset, XPOVIO (selinexor), is marketed in combination with bortezomib and dexamethasone for the treatment of adult patients with multiple myeloma who have received at least one prior therapy. The Company is engaged in evaluating selinexor in certain hematological and solid tumor malignancies, including endometrial cancer, mycosis fungoides (MF) and diffuse large B-cell lymphoma (DLBCL). The Company’s product candidate, eltanexor, is an oral SINE compound like selinexor, that selectively blocks the nuclear export protein XPO1.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Karyopharm Projects $145 Million Total Revenue for 2025 Amid Upcoming Clinical Trials
- Clinical Trial Progress: Karyopharm anticipates releasing top-line data from the Phase 3 SENTRY trial for myelofibrosis in March 2026, which could improve patient outcomes and redefine treatment standards, opening up multi-billion dollar market opportunities for the company.
- Revenue Projections: The company expects total revenue of approximately $145 million for 2025, with net product revenue from XPOVIO (selinexor) estimated at $115 million, indicating sustained growth potential in the cancer treatment sector.
- New Drug Development: The Phase 3 XPORT-EC-042 trial for endometrial cancer is on track to report top-line data in mid-2026, and Karyopharm's collaboration with Foundation Medicine will aid in the precise recruitment of TP53 wild-type patients, enhancing treatment efficacy.
- Market Opportunities: Karyopharm's XPOVIO, as the first oral exportin inhibitor, has received approvals in multiple countries and is expected to meet the high unmet needs of cancer patients globally, driving long-term value creation.
Continue Reading
Karyopharm Grants 1,533 RSUs to New Employees as Inducement
- Employee Incentive Program: Karyopharm Therapeutics granted a total of 1,533 restricted stock units (RSUs) to two new employees, reflecting the company's commitment to attracting talent and strengthening its team.
- Grant Details: These RSU awards were granted on December 31, 2025, under the Company's 2022 Inducement Stock Incentive Plan, ensuring compliance with Nasdaq Listing Rule requirements and fostering long-term commitment from new hires.
- Vesting Arrangement: Each RSU award will vest over three years, with one-third vesting each year, which not only incentivizes employee retention but also enhances overall operational efficiency for the company.
- Strategic Implications: By implementing such incentive measures, Karyopharm not only strengthens its competitive position in cancer treatment but also lays a talent foundation for future innovation and market expansion.
Continue Reading